xamoterol has been researched along with albuterol in 12 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (albuterol) | Trials (albuterol) | Recent Studies (post-2010) (albuterol) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 10,108 | 3,059 | 2,058 |
| Protein | Taxonomy | xamoterol (IC50) | albuterol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.2618 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isogaya, M; Kikkawa, H; Kurose, H; Nagao, T; Sugimoto, Y; Tanaka, R; Tanimura, R | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Blomgren, A; Börjesson, L; Gustavsson, L; Hendrickx, R; Jenvert, RM; Johansson, JG; Lohmann, C | 1 |
| Challenor, VF; Roberts, JA; Waller, DG | 1 |
| McCaffrey, PM; Riddell, JG; Shanks, RG | 2 |
| Fischmeister, R; Jurevicius, J; Skeberdis, VA | 1 |
| Hanratty, CG; Riddell, JG; Silke, B | 1 |
4 trial(s) available for xamoterol and albuterol
| Article | Year |
|---|---|
Is xamoterol safe in chronic airflow obstruction?
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Double-Blind Method; Female; Hemodynamics; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Propanolamines; Respiratory Function Tests; Xamoterol | 1992 |
Selectivity of xamoterol, prenalterol and salbutamol as assessed by their effects in the presence and absence of ICI 118 551.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Blood Pressure; Double-Blind Method; Heart Rate; Humans; Male; Prenalterol; Propanolamines; Xamoterol | 1990 |
The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551.
Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Blood Pressure; Double-Blind Method; Heart Rate; Hemodynamics; Humans; Male; Posture; Prenalterol; Propanolamines; Regional Blood Flow; Tremor; Xamoterol | 1988 |
Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Double-Blind Method; Drug Interactions; Heart Rate; Humans; Male; Prenalterol; Sleep; Statistics as Topic; Xamoterol | 1999 |
8 other study(ies) available for xamoterol and albuterol
| Article | Year |
|---|---|
Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alanine; Albuterol; Amino Acid Substitution; Animals; Binding Sites; Computer Simulation; COS Cells; Ethanolamines; Formoterol Fumarate; Humans; Models, Molecular; Norepinephrine; Procaterol; Propanolamines; Propranolol; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Recombinant Fusion Proteins; Xamoterol | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
Topics: Biological Transport; Chemical Phenomena; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Pharmaceutical Preparations; Reproducibility of Results; Structure-Activity Relationship; Substrate Specificity | 2013 |
Pharmacological characterization of the receptors involved in the beta-adrenoceptor-mediated stimulation of the L-type Ca2+ current in frog ventricular myocytes.
Topics: Albuterol; Animals; Calcium Channels; Calcium Channels, L-Type; Dobutamine; Dose-Response Relationship, Drug; In Vitro Techniques; Isoproterenol; Myocardium; Propanolamines; Rana esculenta; Receptors, Adrenergic, beta; Xamoterol | 1997 |